Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Gd DTPA: a review of clinical indications in central nervous system magnetic resonance imaging Runge VM; Carollo BR; Wolf CR; Nelson KL; Gelblum DYRadiographics 1989[Sep]; 9 (5): 929-58Since its approval for clinical use in mid 1988, Gd DTPA has found widespread application as a contrast agent in MRI. This paramagnetic metal ion chelate is used primarily for enhancement of head and spine lesions. Indications for contrast agent use in MRI are summarized drawing upon experience in more than 600 patients and a review of the literature. Enhancement improves both lesion detection and categorization. In head examinations, we recommend use of Gd DTPA for studies of the internal auditory canal, metastatic disease, infarction, infection, meningeal disease, and primary neoplastic disease. In spine examinations, contrast enhancement is employed both for detection of neoplastic disease and in the postoperative back for the differentiation of scar from recurrent disk herniation. Gd DOTA and Gd DO3A-R are new agents within this same class of contrast media.|*Contrast Media[MESH]|*Gadolinium[MESH]|Brain Neoplasms/diagnosis[MESH]|Central Nervous System Diseases/*diagnosis[MESH]|Gadolinium DTPA[MESH]|Humans[MESH]|Magnetic Resonance Imaging/*methods[MESH]|Organometallic Compounds[MESH]|Pentetic Acid[MESH]|Prospective Studies[MESH]|Spinal Diseases/diagnosis[MESH] |
